Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells $10,471,246.56 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 115,056 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $91.01, for a total transaction of $10,471,246.56. Following the sale, the director owned 647,914 shares of the company’s stock, valued at $58,966,653.14. This trade represents a 15.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth also recently made the following trade(s):

• On Monday, June 22nd, Bruce Booth sold 246,330 shares of Kymera Therapeutics stock. The shares were sold at an average price of $98.52, for a total value of $24,268,431.60.
• On Wednesday, June 17th, Bruce Booth sold 105,071 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.38, for a total value of $9,496,316.98.
• On Wednesday, June 17th, Bruce Booth sold 11,741 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.98, for a total value of $1,056,455.18.
• On Monday, June 22nd, Bruce Booth sold 31,798 shares of Kymera Therapeutics stock. The stock was sold at an average price of $103.75, for a total value of $3,299,042.50.
• On Wednesday, April 22nd, Bruce Booth sold 100 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.08, for a total value of $9,008.00.
• On Wednesday, April 22nd, Bruce Booth sold 5,900 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.96, for a total value of $530,764.00.
• On Wednesday, April 15th, Bruce Booth sold 3,135 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.10, for a total value of $282,463.50.
• On Wednesday, April 15th, Bruce Booth sold 2,200 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.95, for a total value of $197,890.00.
• On Tuesday, April 14th, Bruce Booth sold 4,159 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.97, for a total value of $374,185.23.

Kymera Therapeutics Stock Performance

KYMR opened at $99.87 on Thursday. The stock has a fifty day moving average of $83.90 and a 200-day moving average of $81.77. The company has a market capitalization of $8.22 billion, a P/E ratio of -27.97 and a beta of 2.02. Kymera Therapeutics, Inc. has a fifty-two week low of $36.65 and a fifty-two week high of $105.00.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The business had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. During the same period in the prior year, the company posted ($0.82) earnings per share. Kymera Therapeutics’s revenue was up 55.5% compared to the same quarter last year. On average, equities research analysts predict that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kymera Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Smartleaf Asset Management LLC boosted its position in shares of Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after acquiring an additional 424 shares in the last quarter. Larson Financial Group LLC raised its position in Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares in the last quarter. Osaic Holdings Inc. raised its position in Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after purchasing an additional 1,083 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Kymera Therapeutics during the fourth quarter valued at approximately $63,000. Finally, Raymond James Financial Inc. bought a new stake in Kymera Therapeutics during the second quarter worth $73,000.

Analyst Ratings Changes

Several brokerages have recently commented on KYMR. Morgan Stanley reaffirmed an “overweight” rating and set a $119.00 target price on shares of Kymera Therapeutics in a report on Thursday, April 30th. Stephens boosted their price target on Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a research note on Monday, March 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. Canaccord Genuity Group initiated coverage on Kymera Therapeutics in a research note on Wednesday, May 6th. They set a “buy” rating and a $106.00 price objective on the stock. Finally, BTIG Research dropped their price objective on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Kymera Therapeutics has an average rating of “Moderate Buy” and an average target price of $117.14.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.